What are the current recommendations for the treatment and prophylaxis of suspected or confirmed Ebola virus disease?

Ebola virus disease (EVD): Current treatment and prophylaxis

Use Ebola-specific monoclonal antibodies immediately for confirmed or strongly suspected Zaire ebolavirus (EBOV) and give Ervebo pre-exposure vaccine only to adults at highest occupational risk; these are the only interventions proven to reduce mortality and improve outcomes. 1

1) Immediate actions for suspected or confirmed EVD (prioritize mortality/QoL)

• Isolation + strict PPE (contact + droplet + eye protection; airborne for aerosol-generating procedures).
• Rapid diagnostic testing (rRT-PCR) and species identification; treatment decisions should not wait for speciation if EBOV is likely.

2) Antiviral treatment (Zaire ebolavirus only)

• First-line: Ebola glycoprotein–targeted monoclonal antibodies
  • REGN-EB3 (Inmazeb, FDA-approved) or mAb114 (Ebanga, FDA-approved) reduce 28-day mortality versus comparators; benefit is greatest when started early and with lower viral load [1–1].
  • Strongest, most recent guideline-based evidence: randomized trial in DRC showing REGN-EB3 and mAb114 superiority; FDA approval of Inmazeb in 2020 for EBOV across adult and pediatric patients [1–1].
• Start as soon as EVD is suspected in a compatible outbreak/exposure context consistent with EBOV; do not delay for confirmatory testing when clinical suspicion is high.
• Do NOT use these antibodies for non-Zaire species (e.g., Sudan virus, Bundibugyo); efficacy is uncertain—manage with optimized supportive care alone while awaiting trial/expanded access options 2, 3.

Common pitfalls and how to avoid:

• Delay in initiation increases death odds by ~11% per day of symptoms—treat early [1–1].
• Do not use remdesivir or ZMapp—inferior in the pivotal trial [1–1].

3) Optimized supportive care (reduces mortality to ~40% alone)

• Aggressive fluids and electrolytes with frequent labs; treat shock early.
• Manage hypoxia, bleeding/DIC, secondary infections; provide nutrition [1–1].
• Early transfer to a high-level biocontainment unit when available.

4) Pre-exposure prophylaxis (PrEP) vaccination

• Vaccine: rVSVΔG-ZEBOV-GP (Ervebo)
  • Indication: Adults ≥18 years at highest occupational risk in the U.S.: outbreak responders, staff at federally designated Ebola treatment centers, and BSL-4 laboratorians 1.
  • Dose/storage: single 1 mL IM dose; ultra-cold storage with defined thaw/hold limits 1.
  • Safety: mostly transient systemic symptoms; rare anaphylaxis; avoid with severe rice-protein allergy 1.
• Scope: Protects only against Zaire ebolavirus; does not cover Sudan or other species 1.

Pitfalls:

• Do not use Ervebo as post-exposure prophylaxis (PEP) to prevent disease after a high-risk exposure; evidence and U.S. guidelines support pre-exposure use for high-risk groups only 1. Research on PEP is ongoing and uncertain, especially for non-Zaire species 2, 4.

5) Post-exposure management (occupational or community high-risk contact)

• Immediate steps: risk stratification, quarantine/active monitoring, rapid testing with symptom onset.
• For Zaire exposures: there is no guideline-endorsed, proven PEP. Consider urgent expert consultation and investigational access if available; priority remains early detection and immediate mAb therapy at first symptom 2, 4.
• For non-Zaire exposures (e.g., Sudan): no effective vaccines or therapeutics are established; emphasize monitoring and early supportive care; engage public health authorities promptly 2, 3.

6) Special transmission and survivorship precautions (reduce morbidity/mortality downstream)

• Sexual transmission risk: EBOV RNA can persist in semen for >1 year; documented transmissions up to 470 days after illness onset—enforce semen testing programs and condom use/abstinence until two consecutive negative tests [1–1].
• Breastfeeding: EBOV detected in breast milk up to 16 months; avoid breastfeeding until virologic clearance per public health guidance [1–1].
• Relapse/recrudescence: rare CNS disease months later—maintain follow-up; evaluate new neurologic symptoms urgently [1–1].

7) Triage by species

• If EBOV (Zaire) likely: initiate REGN-EB3 or mAb114 immediately + supportive care; vaccinate eligible high-risk staff with Ervebo (pre-exposure) [1–1].
• If non-Zaire (e.g., Sudan) suspected: monoclonal antibodies/vaccines lack proven benefit—maximize supportive care; enroll in trials if available; reinforce exposure control 2, 3.

Evidence strength and recency:

• Highest-quality, most recent anchored guidance for outcomes comes from CDC/ACIP MMWR recommendations (2021) detailing Ervebo pre-exposure indications and pivotal RCT mortality benefits of REGN-EB3/mAb114; FDA approval of Inmazeb in 2020 confirms clinical utility and applicability across ages [1–1].
• Recent research underscores gaps for non-Zaire species and supports monoclonal antibodies as first-line for EBOV; use to contextualize practice but defer to guideline/label for decisions that affect mortality/QoL 2, 3.